[
  {
    "ts": null,
    "headline": "Gilead Sciences, Inc. (GILD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript",
    "summary": "Gilead Sciences, Inc. (GILD) 44th Annual J.P.",
    "url": "https://finnhub.io/api/news?id=3482d457ee4e65d8413d3fc654fc867daee00c710ca213f1dd6c62fa28a9e9bd",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768232763,
      "headline": "Gilead Sciences, Inc. (GILD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript",
      "id": 138078583,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Gilead Sciences, Inc. (GILD) 44th Annual J.P.",
      "url": "https://finnhub.io/api/news?id=3482d457ee4e65d8413d3fc654fc867daee00c710ca213f1dd6c62fa28a9e9bd"
    }
  },
  {
    "ts": null,
    "headline": "UBS and Citi Go Bullish on Gilead Sciences (GILD)",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the most undervalued blue chip stocks to buy now. On January 7, 2026, reports highlighted that analysts are increasingly confident in Gilead Sciences, Inc. (NASDAQ:GILD)’s short- and medium-term outlook, driven by optimism around the company’s HIV franchise. On that day, UBS analyst Michael Yee upgraded the stock from […]",
    "url": "https://finnhub.io/api/news?id=3afbb2fe454ee95c36d9d540589831cc2221552830486a3bf307096fe433c122",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768210272,
      "headline": "UBS and Citi Go Bullish on Gilead Sciences (GILD)",
      "id": 138071500,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the most undervalued blue chip stocks to buy now. On January 7, 2026, reports highlighted that analysts are increasingly confident in Gilead Sciences, Inc. (NASDAQ:GILD)’s short- and medium-term outlook, driven by optimism around the company’s HIV franchise. On that day, UBS analyst Michael Yee upgraded the stock from […]",
      "url": "https://finnhub.io/api/news?id=3afbb2fe454ee95c36d9d540589831cc2221552830486a3bf307096fe433c122"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences CEO Daniel O'Day: We have the most robust pipeline in company history",
    "summary": "Daniel O’Day, Gilead Sciences CEO and chairman, joins 'Squawk Box' to discuss the advances in medicine, what to expect at the JPMorgan Healthcare Conference today, the company's Yeztugo HIV medication, drug pipeline outlook, impact of AI, and more.",
    "url": "https://finnhub.io/api/news?id=87e539dde7646d7820229d28c082c2a8131e770fff8d6d7c24cd6dfc173f8019",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768208676,
      "headline": "Gilead Sciences CEO Daniel O'Day: We have the most robust pipeline in company history",
      "id": 138075988,
      "image": "https://image.cnbcfm.com/api/v1/image/108251114-17682257611768225758-43458680393-1080pnbcnews.jpg?v=1768225760&w=1920&h=1080",
      "related": "GILD",
      "source": "CNBC",
      "summary": "Daniel O’Day, Gilead Sciences CEO and chairman, joins 'Squawk Box' to discuss the advances in medicine, what to expect at the JPMorgan Healthcare Conference today, the company's Yeztugo HIV medication, drug pipeline outlook, impact of AI, and more.",
      "url": "https://finnhub.io/api/news?id=87e539dde7646d7820229d28c082c2a8131e770fff8d6d7c24cd6dfc173f8019"
    }
  },
  {
    "ts": null,
    "headline": "The Bull Case For Gilead Sciences (GILD) Could Change Following New OncoNano Drug-Delivery Collaboration",
    "summary": "On January 6, 2026, OncoNano Medicine announced a research collaboration with Gilead Sciences to test its ON-BOARD encapsulation technology with a Gilead drug candidate, with OncoNano eligible for upfront, milestone and royalty payments and up to US$300.00 million if Gilead adds a second target. This collaboration underscores Gilead’s continued push to enhance drug delivery and efficacy in its pipeline, potentially reinforcing its focus on innovative therapies. Now we’ll examine how this...",
    "url": "https://finnhub.io/api/news?id=3dcc842b152e5723484bf861e2526dbd746702b6159fd82b1c2a4ff693187676",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768191848,
      "headline": "The Bull Case For Gilead Sciences (GILD) Could Change Following New OncoNano Drug-Delivery Collaboration",
      "id": 138069115,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "On January 6, 2026, OncoNano Medicine announced a research collaboration with Gilead Sciences to test its ON-BOARD encapsulation technology with a Gilead drug candidate, with OncoNano eligible for upfront, milestone and royalty payments and up to US$300.00 million if Gilead adds a second target. This collaboration underscores Gilead’s continued push to enhance drug delivery and efficacy in its pipeline, potentially reinforcing its focus on innovative therapies. Now we’ll examine how this...",
      "url": "https://finnhub.io/api/news?id=3dcc842b152e5723484bf861e2526dbd746702b6159fd82b1c2a4ff693187676"
    }
  }
]